MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Checkpoint Therapeutics Inc

Fechado

SetorSaúde

4.03 -0.25

Visão Geral

Variação de preço das ações

24h

Atual

Mín

3.98

Máximo

4.04

Indicadores-chave

By Trading Economics

Funcionários

23

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+31.19% upside

Dividendos

By Dow Jones

Próximos Ganhos

9 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

207M

Abertura anterior

4.28

Fecho anterior

4.03

Sentimento de Notícias

By Acuity

50%

50%

180 / 386 Ranking em Healthcare

Checkpoint Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de mar. de 2025, 10:23 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma

14 de dez. de 2024, 00:24 UTC

Grandes Movimentos do Mercado

Checkpoint Therapeutics' Shares Rise After Securing First FDA Approval

25 de jul. de 2024, 13:02 UTC

Grandes Movimentos do Mercado

Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab

10 de mar. de 2025, 02:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Checkpoint Controlling Shareholder Fortress Has Agreed to Vote in Favor of Transaction >524715.BY

10 de mar. de 2025, 02:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Pharma, Checkpoint Transaction Expected to Complete in 2Q 2025 >524715.BY

10 de mar. de 2025, 02:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Pharma, Checkpoint, Fortress Biotech Enter Into Royalty Agreement >524715.BY

10 de mar. de 2025, 02:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Checkpoint Shareholders Entitled to Receive Up to Additional $0.70 if Cosibelimab if Approved in EU Prior to Certain Deadlines >524715.BY

10 de mar. de 2025, 02:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Checkpoint Shareholders to Receive Upfront Cash Payment of $4.10/Share, Contingent Value Right >524715.BY

10 de mar. de 2025, 02:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Pharma to Acquire Checkpoint Therapeutics >524715.BY CKPT

10 de mar. de 2025, 02:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Pharma To Acquire Checkpoint Therapeutics >524715.BY CKPT

Comparação entre Pares

Variação de preço

Checkpoint Therapeutics Inc Previsão

Preço-alvo

By TipRanks

31.19% parte superior

Previsão para 12 meses

Média 5.3 USD  31.19%

Máximo 7 USD

Mínimo 4.1 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Checkpoint Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

1

Comprar

2

Manter

0

Vender

Sentimento

By Acuity

180 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

$

Sobre Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.